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were elevated in cases with remarkable inflammatory pain 
and high disease activity. These cytokines decreased after 
therapy, however. Most patients with normal cytokine lev-
els at baseline retained these low levels.
Conclusions The findings reveal the short-term efficacy 
of adalimumab. The remarkably low incidence of HLA-
B27 among our patients indicates that HLA-B distribution 
is different from that in other countries. Serum TNF-α and 
IL-6 levels were not effective as biomarkers for cases with-
out high disease activity, and further research with larger 
samples is needed. The efficacy of TNF blockers, however, 
suggested a potential localized TNF effect was present 
among SpA patients.
Introduction
Spondyloarthritis (SpA) is a group of several related but 
phenotypically distinct disorders that are categorized into 
axial SpA and peripheral SpA, on the basis of primary 
symptom location. According to the most recent Assess-
ment of Spondyloarthritis international Society (ASAS) 
definition, predominantly axial SpA includes the catego-
ries non-radiographic, radiographic axial SpA, and anky-
losing spondylitis (AS), which is regarded as the most 
well-known SpA type, and predominantly peripheral SpA, 
which includes psoriatic arthritis, reactive arthritis, entero-
pathic arthritis, and undifferentiated SpA. Other SpA types 
include acute anterior uveitis, juvenile SpA, and SAPHO 
(synovitis, acne, pustulosis, hyperostosis, and osteitis). The 
primary symptom of axial SpA is insidious inflammatory 
back pain, which is often misdiagnosed because its clini-
cal characteristics are not widely recognized by orthopedic 
doctors. Diagnosis is, therefore, often delayed by several 
years [1].
Abstract 
Background Ankylosing spondylitis (AS) is rarer in Japan 
than in Europe, probably because the European criteria, not 
well known by Japanese general physicians, regard AS as 
a progressive stage of axial spondyloarthritis (SpA). HLA-
B27 is an important diagnostic marker of SpA; however, 
the incidence of the HLA-B27 allele is as low as 0.4 % in 
Japan. For Japanese SpA patients, other HLA alleles and 
clinical findings are required for earlier definitive diagno-
sis, for determining appropriate treatment timing, and for 
disease monitoring.
Methods We investigated the HLA-B alleles of 36 
patients clinically diagnosed with SpA. For 8 axial SpA 
patients we evaluated the short-term efficacy of subcuta-
neous adalimumab injections (40 mg every other week for 
≥11 months). Treatment efficacy was evaluated by use of 
the Bath Ankylosing Spondylitis Activity Index (BASDAI) 
score, and serum TNF-α and IL-6 levels were measured pre 
and post-treatment.
Results Among the 36 Japanese SpA patients, the HLA-
B27 allele occurred infrequently (5.6 %) whereas the 
HLA-B44 and 61 alleles were the most frequently detected 
(25.0 %). We also detected severe bamboo spine on radiog-
raphy in the absence of the HLA-B27 allele. All 8 patients 
with axial SpA experienced significant symptom improve-
ment after adalimumab treatment; the HLA-B27 allele was 
absent from these patients. Serum TNF-α and IL-6 levels 
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SpA is rarer in Japan than among Caucasians. The inci-
dence is 0.48/100,000 and the prevalence 9.5/100,000 per-
son-years among the Japanese, less than 1/10 and 1/200, 
respectively, of those among Caucasians [2]. The relatively 
low values may be the result of the misdiagnosis of SpA as 
mechanical back pain by orthopedic doctors in Japan. Shi-
chikawa et al. [3] reported similar prevalence of SpA and 
rheumatoid arthritis (RA) in Japan.
Several criteria are available for diagnosis of SpA. The 
earliest were the modified New York criteria for AS (1984). 
The Amor criteria for SpA (1990), the ASAS criteria for 
classification of axial SpA (2009), and the ASAS criteria 
for classification of peripheral SpA (2011) depend on the 
presence of HLA-B27. A decision tree for axial SpA diag-
nosis, presented by Rudwaleit et al. [4], enables diagnosis 
of early-stage AS, or non-radiographic SpA, which cannot 
be categorized by use of the modified New York criteria 
because it requires radiological changes in the sacroiliac 
joint for diagnosis. Similar to the other criteria, HLA-B27 
is an important part of the decision tree; however, inclusion 
of HLA-B27 makes it challenging to diagnose SpA among 
Japanese patients because of the low incidence of HLA-
B27, reportedly as low as 0.4 % [5].
Traditional treatment options for SpA in Japan include 
non-steroidal anti-inflammatory drugs (NSAIDs), sys-
temic corticosteroid therapy, and disease-modifying anti-
rheumatic drugs (DMARDs). Since 2010, adalimumab, a 
recombinant fully human anti-tumor necrosis factor (TNF) 
monoclonal antibody, has been available for treatment of 
SpA patients for whom the disease if poorly controlled 
by use of traditional therapy. The efficacy of adalimumab 
has been reported in several countries [6–8]. Recent stud-
ies have shown that early treatment with TNF-blockers can 
achieve a higher clinical response for AS and nonradio-
graphic SpA [9, 10].
Therefore, appropriate criteria and biomarkers to aid in 
diagnosis are needed to enable early use of anti-TNF ther-
apy among Japanese SpA patients.
Owing to the low incidence of HLA-B27 in Japan and 
the presence of increased TNF concentrations in the joints 
of patients with AS [11, 12], serum TNF-α levels could bet-
ter reflect SpA disease activity. Here, we evaluated serum 
cytokines as effective biomarkers of SpA, to assist with 
early diagnosis and assessment of adalimumab treatment 
efficacy. Because some of our patients with typical radio-
graphic SpA, for example bamboo spine, were HLA-B27 
negative, we also investigated the variations in HLA-B 
alleles and clinical characteristics of Japanese SpA patients 
for early definitive diagnosis. The purpose of this study 
was to evaluate the efficacy of adalimumab and to inves-
tigate the variation of HLA-B alleles among Japanese SpA 
patients. We also evaluated serum cytokines as effective 
biomarkers of SpA diagnosis and disease monitoring.
Methods
Patients
We investigated HLA-B alleles among 36 patients who 
were clinically diagnosed with SpA in our institutes and 
who agreed to pay for examination of the HLA alleles. 
Eight of the 36 patients were treated with adalimumab. All 
8 patients experienced enthesitis or insidious inflammatory 
pain in the lower back or sacroiliac joints; they also met the 
definition of AS based on the modified New York criteria. 
All of the patients provided informed consent.
The study was approved by the local ethics committee of 
Fujita Health University and conducted in accordance with 
the World Medical Association Declaration of Helsinki.
Despite previous treatment, which had included one or 
more NSAIDs, opioids, or systemic corticosteroid therapy, 5 
of the 8 patients had active disease, as defined by use of the 
total Bath Ankylosing Spondylitis Activity Index (BASDAI) 
score on a visual analog scale (VAS) ≥4 cm, for >4 weeks at 
the time of adalimumab initiation, and the remaining 3 patients 
had experienced insidious back pain for more than 6 months. 
All 8 patients were administered adalimumab 40 mg subcuta-
neously every other week for at least 11 months.
Data collected
Patient background was investigated by use of the HLA-B 
allele, serum cytokine concentrations of TNF-α and IL-6 
(LSI Medience, Tokyo, Japan), disease duration, and radio-
graphic examination of the sacroiliac joint and the whole 
spinal column.
Outcome evaluations
The total BASDAI and specific item scores were used to 
evaluate the subjective outcomes at baseline and at every 
medical consultation after initiation; the specific item 
scores included fatigue, spinal pain, peripheral arthri-
tis, localized tenderness (enthesitis), intensity of morning 
spinal stiffness, and duration of morning stiffness. The 
objective outcomes were evaluated by use of biological 
examinations: serum levels of C-reactive protein (CRP), 
macrophage-derived cytokines (tumor necrosis factor 
[TNF]-α and interleukin [IL]-6), and erythrocyte sedimen-
tation rate (ESR) (LSI Medience, Tokyo, Japan). CRP lev-
els and ESRs were measured at every medical examination, 
and TNF-α and IL-6 levels were measured at baseline and 
the time of the last observation.
The average and standard deviation of the BASDAI val-
ues for each of the 6 items were measured and compared 
by use of paired t tests; p < 0.05 was regarded as indicative 
of a significant difference.
1072 A. Otsuka et al.
1 3
Results
The age of the 36 Japanese patients (13 men, 23 women) 
who underwent the HLA test was 23–87 years. The average 
age of the 8 Japanese patients (2 men, 6 women) treated 
with adalimumab was 55.8 years, and mean axial SpA dis-
ease duration was 20.9 years (Table 1).
On radiography, one of the male patients had severe 
changes for example a bamboo spine, whereas the other 
male patient had severe enthesitis. For 2 of the patients 
the radiological grade of the bilateral sacroiliac joints 
was IV. Case 2 developed both peripheral symptoms and 
enthesitis, and Case 8 had peripheral symptoms. Metho-
trexate (MTX) was added to the adalimumab therapy for 2 
patients with enthesitis (Cases 2 and 5). Case 4 underwent 
total hip arthroplasty for osteoarthritis. Case 6 had previ-
ously been diagnosed with SAPHO syndrome at another 
hospital, and vertebral sclerosis was observed on radiol-
ogy. Case 7 underwent a cardiac operation for aortic valve 
insufficiency. None of the 8 patients developed uveitis or 
inflammatory bowel disease (Table 1). No patient was posi-
tive for the HLA-B27 allele. Of the 9 HLA-B allele types 
(B7, B27, B35, B39, B44, B51, B52, B61, and B62) that 
are reportedly typical of Japanese SpA patients [13], B35 
and B44 were found for 3 patients, B52 was found for 2 
patients, and B7, B51, B61, and B62 were each found for 
one patient (Table 2).
Of the 36 Japanese patients, radiographic axial SpA 
was observed for 13, and 2 of these 13 were positive for 
the HLA-B27 allele. Non-radiographic axial SpA was 
observed for 23 of the 36 patients; all of the 23 were nega-
tive for the HLA-B27 allele. The B44 and B61 alleles were 
the most frequently found (25.0 %); the B35 (22.2 %) and 
B51(19.4 %) alleles were also frequently found (Table 3).
CRP levels were elevated at baseline for 3 of the 8 
patients undergoing adalimumab therapy, and all became 
normal at the last examination. For 5 patients, CRP levels 
remained normal during the therapy. ESRs were elevated 
for 4 patients at baseline; after therapy they returned to 
normal for 3 patients and remained the same for 1 patient. 
For the 4 patients for whom ESR was normal, at the latest 
observation it remained normal for 3 patients and reached 
an elevated level for 1 patient (Fig. 1).
Serum TNF-α levels were abnormal (≥1.79 pg/dL) for 
2 patients at baseline and became normal at the last obser-
vation for both patients. One patient with a normal TNF-α 
level at baseline had an abnormal level at the last observa-
tion. The levels for 5 patients remained normal: decreased 
for 2 patients, increased for 1 patient, and remained under 
the threshold for 2 patients (0.55 pg/mL) (Fig. 2).
The serum IL-6 level was elevated (≥2.56; 10.7 pg/
mL) for 1 patient at baseline and reached normal levels 
(2.01 pg/dL) at the last observation. One patient who had 
Table 1  Characteristics of patients with spondyloarthritis
DD disease duration, IBD inflammatory bowel disease, NSAID non-steroidal anti-inflammatory drug, SAPHO synovitis, acne, pustulosis, hyperos-
tosis, osteitis
a  X-ray grade of the sacroiliac joint
Case Age/sex DD (years) HLA-B X-ray gradea Remarkable findings and  
past history
Enthesitis Uveitis IBD Concomitant medication
1 52/M 20 B7, B61 IV, IV Bamboo spine − − − NSAID
2 53/M 35 B46, B52 IV, IV Syndesmophyte, peripheral 
type
+ − − Methotrexate, NSAID
3 27/F 10 B44, B35 II, III Iliac joint sclerosis − − − −
4 76/F 5 B13, B52 II, II Total hip arthroplasty − − − −
5 51/F 30 B44, B59 II, III Enthesitis + − − Methotrexate, tramadol, 
acetaminophen
6 63/F 10 B46, B51 II, II Vertebral sclerosis, SAPHO − − − −
7 78/F 40 B44, B35 II, II Aortic valve insufficiency − − − −
8 46/F 17 B62, B35 II, II Axial and peripheral type − − − Tramadol, acetaminophen
Table 2  Gene frequencies of HLA-B alleles in patients with spondy-
loarthritis
HLA-B Number of cases (Case #) Frequency (%)
B7 1 (1) 12.5
B27 0 0
B35 3 (3, 7, 8) 37.5
B39 0 0
B44 3 (3, 5, 7) 37.5
B51 1 (6) 12.5
B52 2 (2, 4) 25.0
B61 1 (1) 12.5
B62 1 (8) 12.5
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a normal baseline serum IL-6 level had an elevated level at 
the last observation, and 6 patients had normal serum IL-6 
levels (that decreased for 4 and increased for 2 patients) 
(Fig. 2).
The total BASDAI score improved for all patients com-
pared with the baseline score (Fig. 3). Seven (87.5 %) 
patients achieved 50 % reduction in the initial BASDAI 
score (BASDAI50 response = remarkably effective). Four 
(50 %) patients experienced rapid clinical improvement 
and achieved a BASDAI50 response within 3 months after 
adalimumab initiation. One (12.5 %) patient achieved 
BASDAI50 between 3 and 6 months, and 2 (25 %) patients 
achieved BASDAI50 within 6–12 months.
One patient became drug-free; another patient who had 
secondary failure dropped out of the study at 11 months. 
We observed no adverse events, including local injection 
fraction, among these cases during adalimumab therapy.
Figure 4 illustrates the mean scores of each of the 6 
BASDAI items at baseline and at the last examination. All 
6 items improved after 12 months of adalimumab therapy, 
with significant alleviation of back pain (p < 0.01), the 
intensity of morning spinal stiffness (p < 0.01), peripheral 
arthritis (p < 0.01), and the duration of morning stiffness 
(p < 0.05).
Cases
Case 1. A 52-year-old man with bamboo spine had been 
experiencing middle back pain and neck stiffness for more 
than 20 years. The patient was HLA-B7 and B61 positive. 
Table 3  Gene frequencies of HLA-B alleles among patients with spondyloarthritis in our study compared with those reported in previous Japa-
nese studies [12, 30]
HLA-B Our patient population (n = 36) (%) Our cases (n = 8) (%) Previous reports from Japan (%) Healthy population (%)
B7 11.1 12.5 11.5 5.2
B27 5.6 0 0.4 0.3
B35 22.2 37.5 13.8 8.6
B39 0 0 10.7 4.4
B44 25.0 37.5 13.0 7.9
B51 19.4 12.5 15.0 8.0
B52 16.7 25.0 24.5 13.9
B61 25.0 12.5 23.7 14.6
B62 8.3 12.5 14.2 7.2
Fig. 1  C-reactive protein (CRP) levels and erythrocyte sedimentation 
rates (ESRs) among patients with spondyloarthritis, before and after 
treatment with adalimumab
Fig. 2  Serum tumor necrosis factor (TNF)-α and interleukin (IL)-6 
levels among patients with spondyloarthritis, before and after treat-
ment with adalimumab
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His cervical spine had the typical characteristics of bamboo 
spine (Fig. 5 left), and a syndesmophyte was present in the 
lumbar spine. The Modified New York radiological sacro-
iliitis criteria were grade 4 (bilateral) (Fig. 5 right). Serum 
CRP, ESR, and IL-6 levels were elevated before adali-
mumab therapy, and improved to normal levels after the 
therapy. The BASDAI score improved remarkably, from 
7.9 to 2.2 after the first injection.
Case 2. A 27-year-old woman with non-radiographic 
axial SpA had clinically suspected axial SpA for 10 years. 
The patient was HLA-B27 negative and B44 and B35 posi-
tive. The Modified New York radiological sacroiliitis cri-
teria were grades 2 (right) and 3 (left) (Fig. 6a). The area 
of the hyperintense signal from the sacroiliac joint on short 
time inversion recovery (STIR) sequence magnetic reso-
nance imaging (MRI) reflected bone marrow edema, which 
is the active inflammatory phase of sacroiliitis (Fig. 6b). 
After 12 months of adalimumab therapy, the area of hyper-
intense signal was of lower intensity (Fig. 6c). The patient’s 
low back pain had also resolved.
Fig. 3  Changes in the Bath 
Ankylosing Spondylitis Activity 
Index (BASDAI) scores for 
patients with spondyloarthritis 
after treatment with adali-
mumab
Fig. 4  Changes in each of the mean Bath Ankylosing Spondylitis Activity Index (BASDAI) item scores for patients with spondyloarthritis, 
before and after treatment with adalimumab *p < 0.01, **p < 0.05, ***p < 0.1
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Discussion
The results of this study indicate that adalimumab was 
effective for short-term management of the symptoms of 
SpA which was not apparent from serum TNF-α or IL-6 
levels. In addition, the incidence of HLA-B27 in this sam-
ple was remarkably low.
For Western and Japanese patients, TNF inhibition 
therapy is highly effective for alleviating the signs and 
symptoms of AS and non-radiographic axial SpA [6–8, 
14–17]. With adalimumab therapy for non-radiographic 
SpA patients from America, Europe, and Australia, the 
mean BASDAI change was −1.9 at the primary endpoint 
at 12 weeks [6]. The previous study of adalimumab therapy 
among Japanese patients with AS achieved −3.4 (−4.2 to 
−2.7) at week 12 [8]. Similarly, this study achieved −2.5 
(−5.7 to −0.4) change of the mean BASDAI at week 12. 
Haibel reported a greater clinical response to TNF-block-
ers with earlier treatment of AS and nonradiographic axial 
SpA [9, 10] Furthermore, compliance with the adalimumab 
therapy probably contributed to the observed, rapid clinical 
improvement in this study.
Previous studies have revealed increased macrophage-
derived cytokine (TNF-α and IL-6) levels among patients 
with AS, and a relationship between IL-6 and disease activ-
ity has been reported [11, 12, 18–20]. In this present study, 
Fig. 5  Radiography of the 
bamboo cervical spine (left) and 
bilateral sacroiliac joints (right) 
of case 1
Fig. 6  Radiography of the 
sacroiliac joints (a) and STIR 
sequence MRI for 1 patient 
with spondyloarthritis before 
(b) and after (c) treatment with 
adalimumab
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serum TNF-α levels remained the same after adalimumab 
administration. Serum IL-6 levels significantly decreased 
after adalimumab administration for 1 (12.5 %) patient 
only, whereas levels remained normal for 5 (62.5 %) 
patients. Therefore, even after the significant efficacy of 
cytokine therapy (TNF blockers and anti-IL-6 receptor 
antibody [21]), other, yet unknown, factors may explain 
the pain and disease activity in SpA. Until we have a bet-
ter understanding of the underlying mechanisms, we sug-
gest the use of serum TNF-α and IL-6 levels to determine 
the appropriate timing of treatment and to monitor disease 
activity among patients with greater disease activity and 
abnormally high cytokine levels. For patients with less dis-
ease activity and normal cytokine levels, the importance of 
cytokine levels as biomarkers remains to be determined. 
Individual differences may exist in the usefulness of serum 
TNF-α and IL-6 levels as biomarkers for diagnosis and 
evaluation of disease activity.
Previous reports have indicated that traditional 
DMARDs, for example MTX and sulfasalazine (SASP), 
are not effective for treatment of AS and axial SpA [22, 23] 
whereas SASP may be effective for peripheral SpA [24, 
25]. Two of the patients in this study with severe enthesis 
and peripheral symptoms experienced greater alleviation 
of their peripheral symptoms on addition of MTX to their 
adalimumab therapy. Therefore, the combined use of MTX 
with adalimumab may be effective for enthesis and periph-
eral symptoms of SpA, and the efficacy may depend on 
each case.
SpA is believed to be strongly associated with HLA-
B27, the incidence of which is reportedly low (0.4 %) in 
Japan. The frequency of HLA-B27 [26] and distribution 
of HLA-B differ, depending on ethnicity, with reported 
differences among SpA patients in Mexico [27], Tunisia 
[28], Alaskan Eskimos [29], and Sub-Saharan Africa [30]. 
Among 253 Japanese SpA patients, the frequency of HLA-
B27 was low whereas the frequencies of B7, B35, B39, 
B44, B51, B52, B61, and B62 were high [13]; this is simi-
lar to the findings in this study (Table 3).
HLA-B27 as a diagnostic criterion for SpA may, there-
fore, not have much importance for Japanese patients. 
Instead, HLA-B typing should be considered for Japanese 
SpA patients, particularly as dependence on HLA-B27 can 
delay SpA diagnosis for Japanese patients.
We suspect that the clinical presentation of SpA (includ-
ing AS) is also quite different for Japanese patients from 
that for European patients. Japanese SpA patients who 
meet the ASAS criteria are more likely to be women, even 
though more men are expected to meet the diagnostic cri-
teria. Fibromyalgia (FM) symptoms are similar to those 
among Japanese female SpA patients, and we found it dif-
ficult to discriminate between nonradiographic axial SpA 
and FM in a few cases. In addition, progression to more 
severe symptoms, for example bamboo spine, in AS may 
not occur as frequently among Japanese SpA patients as 
among European patients. Additional studies are needed 
to enable understanding of the characteristics of Japanese 
patients.
The findings of this study reveal the short-term efficacy 
of adalimumab for 8 Japanese SpA patients. The remark-
ably low incidence of HLA-B27 indicates that variations in 
HLA-B types and symptoms among Japanese SpA patients 
are different from those among SpA patients of other coun-
tries. Serum TNF-α and IL-6 levels were not effective as 
biomarkers for cases without high disease activity, and fur-
ther research with larger samples is needed.
A limitation of this study is that not all patients with 
clinically suspected SpA provided consent for the HLA test 
because the fee is not covered by health insurance, and it is 
very expensive (approximately 30,000 yen, or ~$250) for 
typical patients in Japan. Second, the numbers of samples 
for serum cytokines were not large enough for determina-
tion of their effectiveness as biomarkers.
Conclusion
The findings of our study reveal the short-term efficacy and 
usefulness of adalimumab. The remarkably low incidence 
of HLA-B27 indicates that HLA-B distribution is different 
from that among SpA patients in other countries. Serum 
TNF-α and IL-6 levels were not effective as biomarkers in 
the cases without high disease activity, and further research 
with larger samples is needed.
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